Every Form 4 that Liquidia Corporation (LQDA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LQDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LQDA filings page.
Liquidia (LQDA) officer Michael Kaseta (CFO and COO) reported a Form 4 showing equity settlement and a tax-related sale. On 10/10/2025, he acquired 5,828 shares of common stock upon the conversion of performance stock units, which convert one-for-one into common stock. On 10/13/2025, he sold 11,630 shares at $23.41 per share pursuant to a Rule 10b5-1 plan.
The filing states the sale was made to cover taxes from the settlement of previously granted RSUs and PSUs. Following the transactions, Kaseta beneficially owned 352,646 shares directly. The derivative table lists 52,453 derivative securities beneficially owned after the reported transactions.
Liquidia Corp (LQDA) Chief Commercial Officer Scott Moomaw reported insider transactions. On 10/10/2025, 3,108 common shares were acquired upon settlement of performance stock units at $0 per unit. On 10/13/2025, 4,900 shares were sold at $23.41 pursuant to a Rule 10b5-1 plan; the filing notes the sale covered taxes related to prior RSU/PSU settlements.
Following these transactions, he beneficially owned 153,462 common shares directly and held 27,969 unvested RSUs.
Liquidia Corp. (LQDA) insider activity: Chief Medical Officer Dr. Rajeev Saggar reported a PSU conversion and a tax-related sale. On 10/10/2025, 3,530 performance stock units converted into common stock on a one-for-one basis (code M). On 10/13/2025, 5,327 shares were sold at $23.41 (code S) pursuant to a Rule 10b5-1 plan adopted on December 15, 2023.
Following these transactions, the reporting person beneficially owns 247,930 shares, held directly. The sale was disclosed as covering taxes tied to the settlement of RSUs and PSUs initially granted on January 11, 2023 and January 11, 2024. The officer’s role is listed as Chief Medical Officer.
Liquidia (LQDA) reported an insider transaction by its Chief Accounting Officer. On 10/13/2025, the officer sold 1,238 shares of common stock at $23.41 per share, coded “S,” pursuant to a Rule 10b5-1 plan adopted on December 15, 2023. The filing states the sale was to cover taxes tied to the settlement of restricted stock units granted on January 11, 2024.
After the transaction, the officer beneficially owned 185,411 shares, held directly. Holdings include unvested RSUs from prior grants and 11,869 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Liquidia (LQDA) reported an insider transaction by Chief Human Resource Officer Sarah Krepp. On 10/13/2025, she sold 1,691 shares of common stock at $23.41 per share under a Rule 10b5-1 plan adopted on December 15, 2023. The sale covered taxes tied to RSU settlements from awards granted on January 11, 2024 and July 1, 2024.
After the trade, she beneficially owned 141,439 shares. Her holdings include unvested RSUs from 2024 and 2025 grants and 5,312 shares acquired under the 2020 ESPP.
Liquidia (LQDA) reported insider activity by its Chief Business Officer. On 10/10/2025, the officer settled equity awards, converting 3,906 RSUs and 2,474 PSUs into common stock. On 10/13/2025, 3,670 shares were sold at $23.41 under a Rule 10b5-1 plan to cover taxes tied to those settlements. Following these transactions, the officer beneficially owned 175,690 common shares, held directly. RSUs and PSUs convert one-for-one into common stock, with remaining unvested awards continuing on their stated vesting schedules.